+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Minimal Residual Disease Testing Market by Technology (Flow Cyclometry, Next-Generation Sequencing, Polymerase Chain Reaction), Indication (Leukemia, Lymphoma, Myeloma), End-User - Forecast 2024-2030- Product Image
Global Minimal Residual Disease Testing Market by Technology (Flow Cyclometry, Next-Generation Sequencing, Polymerase Chain Reaction), Indication (Leukemia, Lymphoma, Myeloma), End-User - Forecast 2024-2030- Product Image
Sale

Global Minimal Residual Disease Testing Market by Technology (Flow Cyclometry, Next-Generation Sequencing, Polymerase Chain Reaction), Indication (Leukemia, Lymphoma, Myeloma), End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5847005
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Minimal Residual Disease Testing Market size was estimated at USD 1.83 billion in 2023, USD 2.05 billion in 2024, and is expected to grow at a CAGR of 12.36% to reach USD 4.14 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Minimal Residual Disease Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Minimal Residual Disease Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Minimal Residual Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilus Diagnostics Ltd., Amgen Inc., ARUP Laboratories, AstraZeneca PLC, Asuragen Inc. by Bio-Techne Corporation, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, C2I Genomics Inc., Cergentis B.V., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Genetron Holdings Limited, GRAIL, LLC by Illumina, Inc., Guardant Health, Inc., Integrated DNA Technologies, Inc., Invivoscribe, Inc., Kite Pharma, Inc. by Gilead Sciences, Inc., Laboratory Corporation of America Holdings, Mdxhealth BV, MedGenome Inc, Mission Bio, Inc., Myriad Genetics, Inc., Natera Inc., NeoGenomics Laboratories, Inc., OPKO Health, Inc., Quest Diagnostics incorporated, Sysmex Corporation, and Veracyte, Inc.

Market Segmentation & Coverage

This research report categorizes the Minimal Residual Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Flow Cyclometry
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Indication
    • Leukemia
    • Lymphoma
    • Myeloma
  • End-User
    • Academic & Research Institutes
    • Diagnostic Laboratories
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Minimal Residual Disease Testing Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Minimal Residual Disease Testing Market?
  3. What are the technology trends and regulatory frameworks in the Minimal Residual Disease Testing Market?
  4. What is the market share of the leading vendors in the Minimal Residual Disease Testing Market?
  5. Which modes and strategic moves are suitable for entering the Minimal Residual Disease Testing Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Minimal Residual Disease Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Need for refine treatment decisions for a variety of cancers
5.1.1.2. Rising prevalence of hematologic malignancies among world population
5.1.2. Restraints
5.1.2.1. High cost associated with the MRD testing
5.1.3. Opportunities
5.1.3.1. Evolution of personalized MRD testing techniques
5.1.3.2. Ongoing development of new minimal residual disease testing methods
5.1.4. Challenges
5.1.4.1. Stringent government regulations for the commercialization of MRD
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Minimal Residual Disease Testing Market, by Technology
6.1. Introduction
6.2. Flow Cyclometry
6.3. Next-Generation Sequencing
6.4. Polymerase Chain Reaction
7. Minimal Residual Disease Testing Market, by Indication
7.1. Introduction
7.2. Leukemia
7.3. Lymphoma
7.4. Myeloma
8. Minimal Residual Disease Testing Market, by End-User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Diagnostic Laboratories
8.4. Hospitals
9. Americas Minimal Residual Disease Testing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Minimal Residual Disease Testing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Minimal Residual Disease Testing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Adaptive Biotechnologies Corporation
13.1.2. Agilus Diagnostics Ltd.
13.1.3. Amgen Inc.
13.1.4. ARUP Laboratories
13.1.5. AstraZeneca PLC
13.1.6. Asuragen Inc. by Bio-Techne Corporation
13.1.7. Bio-Rad Laboratories, Inc.
13.1.8. Bristol-Myers Squibb Company
13.1.9. C2I Genomics Inc.
13.1.10. Cergentis B.V.
13.1.11. Exact Sciences Corporation
13.1.12. F. Hoffmann-La Roche Ltd.
13.1.13. Genetron Holdings Limited
13.1.14. GRAIL, LLC by Illumina, Inc.
13.1.15. Guardant Health, Inc.
13.1.16. Integrated DNA Technologies, Inc.
13.1.17. Invivoscribe, Inc.
13.1.18. Kite Pharma, Inc. by Gilead Sciences, Inc.
13.1.19. Laboratory Corporation of America Holdings
13.1.20. Mdxhealth BV
13.1.21. MedGenome Inc
13.1.22. Mission Bio, Inc.
13.1.23. Myriad Genetics, Inc.
13.1.24. Natera Inc.
13.1.25. NeoGenomics Laboratories, Inc.
13.1.26. OPKO Health, Inc.
13.1.27. Quest Diagnostics incorporated
13.1.28. Sysmex Corporation
13.1.29. Veracyte, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET RESEARCH PROCESS
FIGURE 2. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MINIMAL RESIDUAL DISEASE TESTING MARKET DYNAMICS
FIGURE 7. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 6. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYCLOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 10. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 14. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 28. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 31. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 45. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 91. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. MINIMAL RESIDUAL DISEASE TESTING MARKET LICENSE & PRICING

Companies Mentioned

  • Adaptive Biotechnologies Corporation
  • Agilus Diagnostics Ltd.
  • Amgen Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • Asuragen Inc. by Bio-Techne Corporation
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • C2I Genomics Inc.
  • Cergentis B.V.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetron Holdings Limited
  • GRAIL, LLC by Illumina, Inc.
  • Guardant Health, Inc.
  • Integrated DNA Technologies, Inc.
  • Invivoscribe, Inc.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • Mdxhealth BV
  • MedGenome Inc
  • Mission Bio, Inc.
  • Myriad Genetics, Inc.
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics incorporated
  • Sysmex Corporation
  • Veracyte, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.05 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.14 Billion
Compound Annual Growth Rate12.3%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Minimal Residual Disease Testing Market by Technology, Application, End User, and Region 2024-2032 - Product Image

Minimal Residual Disease Testing Market by Technology, Application, End User, and Region 2024-2032

  • Report
  • 141 Pages
  • Global
From
Minimal Residual Disease Testing: Global Markets and Technologies - Product Image

Minimal Residual Disease Testing: Global Markets and Technologies

  • Report
  • 152 Pages
  • Global
From
Minimal Residual Disease Testing Global Market Report 2024 - Product Image

Minimal Residual Disease Testing Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Breast Cancer Liquid Biopsy Testing Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 182 Pages
  • Global
From
Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 185 Pages
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.